X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Natco Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs NATCO PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. NATCO PHARMA FRESENIUS KABI ONCO./
NATCO PHARMA
 
P/E (TTM) x 22.1 30.4 72.9% View Chart
P/BV x 3.1 23.0 13.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   NATCO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
NATCO PHARMA
Mar-14
FRESENIUS KABI ONCO./
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs176877 20.1%   
Low Rs79424 18.5%   
Sales per share (Unadj.) Rs37.7223.4 16.9%  
Earnings per share (Unadj.) Rs5.131.1 16.4%  
Cash flow per share (Unadj.) Rs6.740.3 16.7%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5219.5 19.4%  
Shares outstanding (eoy) m158.2333.07 478.5%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x3.42.9 116.0%   
Avg P/E ratio x25.020.9 119.4%  
P/CF ratio (eoy) x18.916.1 117.2%  
Price / Book Value ratio x3.03.0 101.0%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m20,13521,504 93.6%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7031,128 62.4%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,9637,389 80.7%  
Other income Rs m18167 10.8%   
Total revenues Rs m5,9817,556 79.2%   
Gross profit Rs m1,4301,793 79.7%  
Depreciation Rs m258304 84.7%   
Interest Rs m-26366 -7.1%   
Profit before tax Rs m1,2161,290 94.3%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342309 110.9%   
Profit after tax Rs m8061,027 78.4%  
Gross profit margin %24.024.3 98.8%  
Effective tax rate %28.123.9 117.6%   
Net profit margin %13.513.9 97.2%  
BALANCE SHEET DATA
Current assets Rs m5,1023,681 138.6%   
Current liabilities Rs m2,3853,123 76.4%   
Net working cap to sales %45.67.6 602.6%  
Current ratio x2.11.2 181.4%  
Inventory Days Days15089 167.7%  
Debtors Days Days11359 193.0%  
Net fixed assets Rs m5,1487,685 67.0%   
Share capital Rs m158331 47.8%   
"Free" reserves Rs m6,5566,670 98.3%   
Net worth Rs m6,7327,259 92.7%   
Long term debt Rs m952955 99.7%   
Total assets Rs m10,38811,957 86.9%  
Interest coverage x-45.84.5 -1,012.3%   
Debt to equity ratio x0.10.1 107.5%  
Sales to assets ratio x0.60.6 92.9%   
Return on assets %7.511.7 64.4%  
Return on equity %12.014.2 84.6%  
Return on capital %14.620.7 70.5%  
Exports to sales %74.539.4 189.2%   
Imports to sales %24.85.7 434.6%   
Exports (fob) Rs m4,4412,908 152.7%   
Imports (cif) Rs m1,477421 350.8%   
Fx inflow Rs m5,2983,445 153.8%   
Fx outflow Rs m1,772703 252.2%   
Net fx Rs m3,5252,743 128.5%   
CASH FLOW
From Operations Rs m1,2741,440 88.5%  
From Investments Rs m-1,204-1,089 110.6%  
From Financial Activity Rs m-196-353 55.6%  
Net Cashflow Rs m-126-1 8,476.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 81.0 1.5 5,510.2%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 9.6 16.6 57.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   42,599 25,395 167.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  SHASUN PHARMA  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Positive Note; Apollo Micro Systems IPO Lists at 74% Premium(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the energy sector and IT sector witnessing maximum buying interest.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS